Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA (donidalorsen) at ACAAI 2026 Annual Meeting
Nov 12, 2026, 10:06 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive long-term efficacy data could support future uptake and revenue potential for DAWNZERA if safety and regulatory status remain favorable; commercial impact is conditional on data details, label, and payer coverage.
AI summary
What happened, with direct paths to the underlying reporting
Ionis presented new long-term data at ACAAI 2026 showing durable efficacy and disease control for DAWNZERA (donidalorsen).
Ionis presented new long-term data supporting durable efficacy and disease control for DAWNZERA (donidalorsen) at the ACAAI 2026 Annual Meeting.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Ionis Pharmaceuticals and Roche disclosed prespecified interim Phase 3 IMAgINATION results for sefaxersen in adults with primary IgA nephropathy, showing a statistically significa…
Ionis and Otsuka reported that their Phase 3 therapy for SOD1-ALS met its primary endpoint, fueling optimism for a regulatory filing timeline. If detailed data support durability…
Novartis reported HARBOR DM1 failure for del-desiran and pelacarsen's Lp(a)HORIZON also missed benefits, though lowered Lp(a) levels were achieved. Ionis faces near-term pressure…
Novartis disclosed that pelacarsen failed its primary endpoint in Phase III Lp(a) HORIZON, triggering a pronounced pre-market sell-off. Ionis, as the licensee, could see impacts t…
